Saturday 17 October 2026 Export DOCS’s income statement to Excel — free account

Doximity, Inc.

DOCS Healthcare Health Information Services

Doximity, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $644.9 million, up 13.1% from fiscal 2025. In the quarter to June 2026, revenue grew 7.34%, EPS fell 53.6% and free cash flow fell 34.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

30.97 0.53 −1.68%

Follow DOCS

Alert me

Market cap: $5.6B
P/E: 34.8×
Fwd P/E: 26.2×
Dividend yield: —
F-score: 5/9
Altman Z: 17.11
Beneish M: −2.93
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	1	2	2	1	2	1	1	3	3	1

Insider Ownership 32.89%

Capital & Financial Ratios $m

Market Cap 5,610.00

Revenue 655.57

Net Income 167.05

Free Cash Flow 297.03

Net Debt (687.79)

Current Ratio 6.08

Debt/Equity 0.00

P/E ratio 34.80

Fwd P/E 26.20

P/S ratio 8.62

P/B ratio 6.17

Past 5Y EPS Growth 13.18%

This Y EPS Growth (11.36%)

Next Y EPS Growth 15.55%

Next Y revenue growth 38.20%

Next 5Y EPS Growth 6.93%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 24.19%

10-year low 10-year high

P/S against its own 10 years 13.03%

10-year low 10-year high

P/B against its own 10 years 32.96%

10-year low 10-year high

EV/Sales against its own 10 years 14.91%

10-year low 10-year high

EV/FCF against its own 10 years 14.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	763	916	749	688
Receivables	101	128	145	178
Inventory	—	—	—	—
Other	—	—	—	—
	913	1,089	944	914

	2024	2025	2026	Q'26
Payables	2	1	4	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	147	156	155	150

Compound Annual Growth %

	10y	5y	3y
Sales	—	25.53%	15.45%
Cash Flow	—	31.52%	22.04%
Earnings	—	55.51%	20.23%
Book Value	—	45.03%	(0.53%)

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	157	—	—	—	—
’26	146	169	185	145	645
’25	127	137	169	138	570
’24	108	114	135	118	475
’23	91	102	115	111	419
’22	73	79	98	94	344
’21	36	45	59	67	207

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	42	—	—	—	—
’26	62	94	61	110	326
’25	41	68	65	98	273
’24	57	13	50	64	184
’23	45	40	49	47	180
’22	33	19	27	47	127
’21	9	13	24	38	83

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	40	—	—	—	—
’26	60	92	59	107	317
’25	(131)	237	63	97	267
’24	56	12	49	62	178
’23	43	38	47	46	173
’22	32	18	26	45	121
’21	8	11	23	37	78

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	0.13	—	—	—	—
’26	0.27	0.31	0.31	0.10	0.98
’25	0.21	0.22	0.37	0.31	1.11
’24	0.13	0.15	0.24	0.20	0.72
’23	0.10	0.12	0.16	0.14	0.53
’22	0.09	0.17	0.26	0.16	0.70
’21	0.02	0.11	0.17	0.23	0.53

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	—	—	—	—	41.17	22.91	19.71	22.96	43.25	17.15	Analyst estimates 2027–2029 Powerpack
	High	—	—	—	—	107.79	64.95	40.12	61.75	85.21	46.75
People
People	Employees	—	—	—	—	713	887	977	827	830	880
	Revenue/emp, $m	—	—	0.00	0.00	0.29	0.39	0.43	0.57	0.69	0.73
Income, $m
Income, $m	Revenue	—	—	86	116	207	344	419	475	570	645
	Gross margin, %	—	—	87.29	87.20	84.92	88.42	87.24	89.34	90.20	89.09
	EBT	—	—	8	24	58	114	133	185	264	250
	EBT margin, %	—	—	9.25	20.20	27.92	33.18	31.78	38.96	46.21	38.77
	Net income	—	0	8	30	50	155	113	148	223	196
	Depreciation	—	—	6	6	11	19	22	14	9	20
Per share, $
Per share, $	Revenue	—	—	1.33	1.74	2.78	2.10	2.17	2.50	3.05	3.45
	Earnings	—	—	0.12	0.45	0.68	0.82	0.58	0.78	1.19	1.05
	Cash flow	—	—	0.24	0.39	1.12	0.77	0.93	0.97	1.46	1.75
	Capex	—	—	(0.02)	(0.06)	(0.06)	(0.03)	(0.03)	(0.03)	(0.03)	(0.05)
	Free cash flow	—	—	0.22	0.33	1.05	0.74	0.90	0.94	1.43	1.70
	Book value	—	—	0.00	1.24	1.99	5.37	5.00	4.74	5.79	5.08
	Shares, m	—	—	64	67	74	163	193	190	187	187
Valuation, ×
Valuation, ×	P/E	—	—	78.47	78.47	78.47	67.91	54.88	33.43	48.76	22.40
	P/S	—	—	19.04	19.04	19.04	24.79	14.93	10.56	19.01	6.76
	P/B	—	—	59.03	59.03	59.03	9.69	6.47	5.57	10.01	4.58
	EV/Sales	—	—	18.36	18.36	18.36	22.46	12.92	8.96	17.40	5.60
	EV/FCF	—	—	48.46	48.46	48.46	63.85	31.22	23.89	37.22	11.36
Cash, $m
Cash, $m	Operating cash flow	—	—	15	26	83	127	180	184	273	326
	Capex	—	—	(1)	(4)	(5)	(6)	(6)	(6)	(7)	(9)
	Free cash flow	—	—	14	22	78	121	173	178	267	317
Balance, $m
Balance, $m	Working capital	—	—	—	67	107	793	836	766	932	789
	Total debt	—	—	—	2	1	1	16	—	—	—
	Net debt	—	—	—	(86)	(143)	(798)	(841)	(763)	(916)	(749)
	Shareholders’ equity	—	—	—	83	148	879	966	901	1,083	951
Returns, %
Returns, %	ROA	—	—	0.00	15.59	11.04	21.44	10.60	13.32	19.05	16.42
	ROIC	—	—	0.00	0.00	587.87	88.17	62.50	73.95	85.27	66.42
	ROE	—	—	0.00	31.91	63.51	28.19	12.23	15.81	22.50	19.28

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TEM Tempus AI, Inc.	$12.8B	— (loss-making)	— (loss-making)	+21.56% (above 0%: growing)	n/m	−153.72% (below 0%: shrinking)	64.45%	(19.85%)	Compare
BTSG BrightSpring Health Services, Inc.	$12.3B	34.0×	37.6×	+23.05% (above 0%: growing)	+192.86% (above 0%: growing)	−39.62% (below 0%: shrinking)	12.72%	3.37%	Compare
TXG 10x Genomics	$9.4B	— (loss-making)	— (loss-making)	−12.65% (below 0%: shrinking)	n/m	−4.61% (below 0%: shrinking)	74.48%	(12.95%)	Compare
HNGE Hinge Health Inc.	$8.5B	73.5×	39.4×	+53.00% (above 0%: growing)	n/m	+441.14% (above 0%: growing)	86.44%	19.00%	Compare
HQY HealthEquity, Inc.	$7.7B	33.0×	30.2×	+7.64% (above 0%: growing)	+14.49% (above 0%: growing)	−3.44% (below 0%: shrinking)	73.55%	28.14%	Compare
DOCS Doximity, Inc.	$5.6B	34.8×	26.2×	+7.34% (above 0%: growing)	−53.57% (below 0%: shrinking)	−34.14% (below 0%: shrinking)	84.87%	21.48%
WAY Waystar Holding Corp.	$5.4B	38.0×	22.4×	+18.11% (above 0%: growing)	+10.53% (above 0%: growing)	−52.42% (below 0%: shrinking)	69.44%	23.79%	Compare
HTFL Heartflow, Inc.	$4.4B	— (loss-making)	— (loss-making)	+47.57% (above 0%: growing)	n/m	+62.62% (above 0%: growing)	83.00%	(27.93%)	Compare
PRVA Privia Health Group, Inc.	$2.9B	102×	87.8×	+21.39% (above 0%: growing)	+250.00% (above 0%: growing)	−86.20% (below 0%: shrinking)	9.93%	1.86%	Compare
Median of peers	$8.1B	38.0×	37.6×	+21.48%	+103.68%	−22.11%	71.50%	2.62%

All 51 Health Information Services stocks →

Doximity, Inc. (DOCS) key facts

Strength: Doximity, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $644.9 million, up 13.1% from fiscal 2025.
Doximity, Inc. (DOCS) is a Health Information Services company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, DOCS traded at $30.97, a market capitalization of $5.6 billion.
Return on equity was 19.3% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 17.11 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.